IGC Pharma profit margin IGC
Gross, operating and net profit as a share of revenue over the last twelve months, from 2012.
- Net margin, 12 months
- n/m
- not a meaningful number
- Peer median
- 3.7%
IGC Pharma's net margin works out at −702% over the last twelve months, but it is not a meaningful number: a margin outside minus 100% to 100% is moved by items that are not sales.
Profit margin over time
GrossOperatingNet
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | n/a | n/a | 48.7% |
| FY2025 | n/a | n/a | 37.6% |
| FY2024 | n/a | n/a | 54.5% |
| FY2023 | n/a | n/a | 48.5% |
| FY2022 | n/a | n/a | 48.9% |
| FY2021 | n/a | n/a | 12.6% |
| FY2020 | n/a | n/a | 2.8% |
| FY2019 | −80.1% | −90.7% | 2.6% |
| FY2018 | −84.1% | −84.2% | 3.7% |
| FY2017 | n/a | n/a | 37.0% |
| FY2016 | −44.5% | −45.6% | 13.2% |
| FY2015 | −59.9% | −56.5% | 7.5% |
| FY2014 | n/a | n/a | n/a |
| FY2013 | −28.0% | −30.9% | 19.1% |
| FY2012 | n/a | n/a | −14.7% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year |
|---|---|---|---|
| Q2 FY26 | n/a | n/a | |
| Q1 FY26 | n/a | n/a | |
| Q4 FY25 | n/a | n/a | |
| Q3 FY25 | n/a | n/a | |
| Q1 FY25 | n/a | n/a | |
| Q4 FY25 | n/a | n/a | |
| Q3 FY25 | n/a | n/a | |
| Q2 FY25 | n/a | n/a | |
| Q1 FY25 | n/a | n/a | |
| Q4 FY24 | n/a | n/a | |
| Q3 FY24 | n/a | n/a | |
| Q2 FY24 | n/a | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest IGC Pharma's size, closest first, today.
| Company | Profit margin |
|---|---|
| IGCIGC Pharma | n/m |
| ATNMActinium Pharmaceuticals | n/m |
| SPROSpero Therapeutics | 15.7% |
| LFVNLifevantage | 2.8% |
| NATRNatures Sunshine Products | 3.7% |
| Peer median | 3.7% |
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on IGC Pharma
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.